The use of epoetin has in Europe been restricted to the intravenous i.v. route in patients on hemodialysis. This study is aimed at investigating impacts of this change in policy. We retrospectively compared 45 hemodialysis patients treated with epoetin alpha beta subcutaneously subcutaneous s.c. period for 12 months before and 12 months after
The NICE study data indicate costs of £167.68 for infusion and £3.32 for subcutaneous routes of adminstraton. 15 However in the NICE figures the cost analysis did not take into account wider direct and indirect costs whilst the subcutaneous administration cost was based on hospital administration rather than on home delivery and
The objective of this study was to examine patients’ reasons for choosing to keep with their IV infusions or to switch to subcutaneous SC injections. This study was based upon a self
Sep 09 2018 Introduction The quality of interventions in children is largely dependent on their control. Hence this study compared the sedative effects of subcutaneous SC and intravenous IV Midazolam in pediatric sedation induction. Methods This randomized clinical trial was conducted on children aged 1 6 years presenting to emergency departments of
May 12 2014 Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma results from a two stage phase IB study.
Sep 07 2017 Overview. The purpose of this study is to show that subcutaneous SC administration of daratumumab co formulated with recombinant human hyaluronidase PH20 Dara SC is non inferior to intravenous IV administration of daratumumab Dara IV in terms of the overall response rate ORR and maximum trough concentration Ctrough .
An overall response was seen in 108 41 of 263 patients in the subcutaneous group and 96 37 of 259 in the intravenous group relative risk 1 11 95 CI 0 89–1 37 . The geometric means ratio for C trough was 107 93 90 CI 95 74–121 67 and the maximum C trough was 593 μg/mL SD 306 in the subcutaneous group and 522 μg/mL
Jul 15 2015 The authors aimed to compare the safety and effectiveness of SC tocilizumab compared to IV tocilizumab over a 97 week period.. 1 262 patients participated in this study. For the first 24 weeks patients were randomly assigned to receive either SC tocilizumab or IV tocilizumab both in combination with other RA drugs.After 24 weeks patients receiving SC
Dec 13 2019 Ismael G Hegg R Muehlbauer S et al. Subcutaneous versus intravenous administration of neo adjuvant trastuzumab in patients with HER2 positive clinical stage I III breast cancer HannaH study
In this study the main goal was to compare the effectiveness of sumatriptan versus valproate in an acute migraine. A randomized clinical trial including 37 patients with an acute migraine was considered to compare the effectiveness of sumatriptan versus valproate. The patients were divided into two groups.
During the study all authors were employed by Methodist Le Bonheur Healthcare Memphis TN.. BACKGROUND Granulocyte colony stimulating factor G CSF is often used to expedite neutrophil recovery after hematopoietic stem cell transplant HSCT . Although the subcutaneous SQ route is the preferred method of administration intravenous IV administration may be
To our knowledge this is the largest study to present data comparing subcutaneous with intravenous bortezomib in newly diagnosed myeloma. We show better tolerance and similar overall response rates for subcutaneous compared to intravenous bortezomib. The clinical trial is registered at eudract.emaropa as n. 2010 019173 16. Introduction
Nov 12 2013 Hoffmann La Roche 2013 A study to compare subcutaneous versus intravenous MabThera rituximab in combination with chemotherapy in patients with chronic lymphocytic leukemia. Retrieved onpublished at whilst December year 1111 from ClinicalTrials.gov. Accessed 1 October 28.
Mateos M V. et al. Efficacy and safety of the randomized open label non inferiority phase 3 study of subcutaneous SC versus intravenous IV daratumumab DARA administration in patients pts with relapsed or refractory multiple myeloma RRMM COLUMBA. Abstract #8005. American Society of Clinical Oncology meeting Chicago US. 2019 Jun 02.
The objective of this study was to compare the effectiveness of initial treatment with subcutaneous versus oral MTX for the treatment of early RA ERA in routine clinical care. Our primary research question was to determine whether patients starting subcutaneous MTX were more or less likely to require a change in treatment over the first year.
Sep 01 1998 The aim of the present study was to investigate the safety and efficacy of intravenous vs. subcutaneous IL‐2 regimes using 9 Mio I.U. of IL‐2 in combination with protease‐inhibitor therapy. Design All patients were treated with a combination of two reverse transcriptase inhibitors and a protease‐inhibitor prior to IL‐2 administration
Intravenous Versus Subcutaneous Dosing of Epoetin Alfa iu Hemodialysis Patients Emil P. Paganini MD Joseph W. Eschbach MD J. Michael Lazarus MD On completing the initial SC three times per week stage of the study patients were randomized to one of three alfa dose requirements for the IV versus SC
Nov 09 2013 Intravenous IV granulocyte colony stimulating factor G CSF might be safer and more convenient than subcutaneous SC administration to hospitalized hemato oncological patients receiving chemotherapy. To compare IV vs. SC G CSF administration we conducted a randomized open label trial. We included
Sep 03 2010 A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra Tocilizumab in Participants With Moderate to Severe Active Rheumatoid Arthritis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.
Jan 29 2014 The intervention consisted of the administration of up to 1.5 l/day/route for 72 hours subcutaneous vs. intravenous evaluating the variations in biochemical parameters urea creatinine osmolarity clinical outcome and route related complications.
Mean rHuEPO dose at the time of stabilization was significantly lower in the subcutaneous group compared to the intravenous 205.9 / 135.4 vs. 274.1 /
Purpose This two stage phase IB study investigated the pharmacokinetics and safety of subcutaneous SC versus intravenous IV administration of rituximab as maintenance therapy in follicular lymphoma. Patients and methods In stage 1 dose finding 124 patients who responded to rituximab induction were randomly assigned to SC rituximab 375 mg/m2 625
Nov 30 2021 The purpose of this study was to evaluate whether or not subcutaneous casirivimab and imdevimab is associated with reduced risk adjusted 28 day clinical outcomes compared to non treatment with monoclonal antibodies. We also sought to evaluate the similarity of clinical outcomes comparing subcutaneous with intravenous treatment
Introduction For prophylaxis of hereditary angioedema HAE attacks replacement therapy with human C1 inhibitor C1 INH treatment is approved and available as intravenous C1 INH IV Cinryze and subcutaneous C1 INH SC HAEGARDA preparations. In the absence of a head to head comparative study of the two treatment modalities an indirect comparison of
Jun 01 2018 The subcutaneous route of administration is an established effective method of opioid delivery with well described and more favorable pharmacokinetics than the intravenous route. Subcutaneous injection of morphine demonstrates equivalent bioavailability while achieving a slightly delayed rise to maximum plasma concentration compared with
De Cock E Pivot X Hauser N et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2 positive early breast cancer. Cancer Med. 20165 3 389 397. doi 10.1002/cam4.573 PubMed Google Scholar Crossref
Přijďte na dny otevřených dveří . Výzkum
BQ+ Medical not only produce components for manufacturers all over the world, but also provide private label manufacturing for leading brand distributors in different countries.
No.18,Cheye Road,Songjiang District,Shanghai 201611 China.
Tel: 86-021-57743953
Email: [email protected]
Copyright © BQ PLUS MEDICAL CO., LTDSitemap | Contact Us |
